腹膜透析相关性腹膜炎患者的万古霉素首次血药浓度影响因素分析

姜俞濛 ,  李建中 ,  杭永付 ,  杨友静 ,  陶莎莎 ,  胡坤 ,  徐德宇 ,  卢国元

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (9) : 1221 -1230.

PDF (1079KB)
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (9) : 1221 -1230. DOI: 10.12092/j.issn.1009-2501.2026.09.008
临床药理学

腹膜透析相关性腹膜炎患者的万古霉素首次血药浓度影响因素分析

作者信息 +

Influencing factors of the first serum concentration of vancomycin in patients with peritoneal dialysis-related peritonitis

Author information +
文章历史 +
PDF (1104K)

摘要

目的: 分析腹膜透析相关性腹膜炎(peritoneal dialysis-related peritonitis,PDRP)患者腹腔内注射万古霉素后血药浓度的影响因素及与临床疗效的相关性。方法: 回顾性收集 2021 年 1 月至 2024 年 8 月苏州大学附属第一医院 37 例接受腹腔 1 g 万古霉素给药并监测血药浓度的 PDRP 患者临床资料,于第 2 次给药前 0.5 h 采血,测定首次血药浓度(谷浓度)。结果: 17 例既往有腹膜炎感染史的 PDRP 患者首次血药浓度为 11.22(9.46, 11.93)μg/mL, 显著高于 20 例无感染史的 PDRP 患者首次血药浓度[8.66(7.84,9.51)μg/mL(P<0.01)];Logistic 回归分析提示腹膜炎感染史及给药间隔时长是首次血药浓度的独立影响因素(P<0.01);腹膜炎感染史在任何给药间隔下均能提高浓度,而给药间隔时间仅在无感染史患者中起明显作用;万古霉素治疗前、后,腹透液细胞成分及转阴天数在高浓度组与低浓度组差异无统计学意义(P>0.05);两组治疗后腹透液细胞成分和 C 反应蛋白(C-reactive protein,CRP)水平均较治疗前下降(P<0.05);高浓度组患者治疗后 CRP 水平较低浓度组患者高(P<0.05)。结论: 既往腹膜炎感染史和给药间隔时长可显著影响万古霉素首次血药浓度,但首次浓度水平对 PDRP 患者的临床疗效和转阴天数无显著影响。

Abstract

AIM: To investigate the factors influencing the first serum concentration of vancomycin and its relationship to clinical efficacy in patients with peritoneal dialysis-related peritonitis (PDRP) receiving intraperitoneal administration. METHODS: We collected clinical data from 37 PDRP patients treated at The First Affiliated Hospital Of Soochow University between January 2021 and August 2024. All patients received 1 g intraperitoneal vancomycin and underwent serum concentration monitoring. Blood samples were drawn 0.5 h before the second dose to determine the first serum concentration. RESULTS: Seventeen patients with a prior history of peritonitis had a significantly higher first serum concentration[11.22(9.46,11.93) μg/mL] than 20 patients without such history[8.66(7.84,9.51) μg/mL;P<0.01]. Logistic regression identified that both prior peritonitis history and dosing interval duration were independent factors affecting the first serum concentration (P<0.01). A history of peritonitis elevates the first serum concentration at any dosing interval, whereas dosing interval significantly impacts concentrations only in patients without such a history. Before and after vancomycin treatment, there was no significant difference between the high-concentration group and the low-concentration group in the cell components of peritoneal fluid or time to negative culture conversion (P>0.05). Both groups showed significant reductions in the cell components of peritoneal fluid and C-reactive protein (CRP) levels post-treatment compared to baseline (P<0.05). Post-treatment CRP levels were significantly lower in the low-concentration group than in the high-concentration group (P<0.05). CONCLUSION: A history of prior peritonitis and the length of the dosing interval significantly affect the first serum concentration of intraperitoneal vancomycin in PDRP patients; However, the absolute first serum concentration level does not appear to influence clinical efficacy or time to culture negativity.

关键词

腹透相关性腹膜炎 / 万古霉素 / 血药浓度 / 影响因素

Key words

peritoneal dialysis-related peritonitis / vancomycin / serum concentration / influential factor

引用本文

引用格式 ▾
姜俞濛,李建中,杭永付,杨友静,陶莎莎,胡坤,徐德宇,卢国元. 腹膜透析相关性腹膜炎患者的万古霉素首次血药浓度影响因素分析[J]. 中国临床药理学与治疗学, 2026, 31(9): 1221-1230 DOI:10.12092/j.issn.1009-2501.2026.09.008

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Yu J, Zhu L, Ni J, et al. Technique failure in peritoneal dialysis-related peritonitis: risk factors and patient survival[J].Ren Fail, 2023, 45(1): 2205536.

[2]

Li PKT, Chow KM, Cho Y, et al. ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment[J].Perit Dial Int, 2022, 42(2): 110-153.

[3]

中国腹膜透析相关感染防治专家组. 腹膜透析相关感染的防治指南[J].中华肾脏病杂志, 2018, 34(2): 139-148.

[4]

Ma Y, Geng Y, Jin L, et al. Serum vancomycin levels predict the short-term adverse outcomes of peritoneal dialysis-associated peritonitis[J].Perit Dial Int, 2023, 43(1): 37-44.

[5]

谢静, 张莹, 沈正泽. 万古霉素腹腔给药治疗腹膜透析相关性腹膜炎的血药浓度监测结果分析[J].中国医院用药评价与分析, 2024, 24(7): 789-792.

[6]

杭永付, 徐德宇, 薛领, 等. 腹透相关性腹膜炎腹腔给予万古霉素血药浓度的特点及与疗效的关系[J].中国药学杂志, 2019, 54(12): 1031-1034.

[7]

何娜, 苏珊, 翟所迪, 等. 《中国万古霉素治疗药物监测指南 (2020 更新版)》解读[J].临床药物治疗杂志, 2021, 19(1): 12-16.

[8]

蔡乐, 张庆涛, 谢大洋, 等. 腹膜透析相关腹膜炎患者万古霉素血药浓度监测结果分析[J].中国药物应用与监测, 2021, 18(1): 13-17.

[9]

Stevenson S, Tang W, Cho Y, et al. The role of monitoring vancomycin levels in patients with peritoneal dialysis-associated peritonitis[J].Perit Dial Int, 2015, 35(2): 222-228.

[10]

辛洋洋, 阳晓. 腹膜透析标准化临床结局的研究进展[J].中华肾脏病杂志, 2023, 39(8): 630-634.

[11]

董雪, 任天舒, 孙飞龙, 等. 腹膜透析相关性腹膜炎初始经验抗菌治疗方案研究[J].临床军医杂志, 2017, 45(3): 300-303.

[12]

Dogan CZ, Kara E, Pinar A, et al. Therapeutic drug monitoring in patients treated with vancomycin: a single center, prospective, observational, real-world study[J].Eur J Clin Microbiol Infect Dis, 2025, 44(9): 2159-2165.

[13]

Deacon E, Canney M, McCormick B, et al. The association between serum vancomycin level and clinical outcome in patients with peritoneal dialysis associated peritonitis[J].Kidney Int Rep, 2023, 8(12): 2646-2653.

[14]

袁世轩, 吕子彦, 杨勇, 等. 模型引导下的万古霉素血药浓度监测临床研究[J].中国临床药理学与治疗学, 2024, 29(12): 1344-1352.

[15]

Blowey DL, Warady BA, Abdel-Rahman S, et al. Vancomycin disposition following intraperitoneal administration in children receiving peritoneal dialysis[J].Perit Dial Int J Int Soc Perit Dial, 2007, 27(1): 79-85.

[16]

Liu W, Qiao Z, Xu Y, et al. Adjusting dialysis dose (Kt) scaled to body surface area (BSA) could be a more logical approach[J].PLoS One, 2024, 19(10): e0311175.

[17]

王牡丹, 黄丽娃, 陈连国, 等. 腹透相关性腹膜炎患者血清万古霉素谷浓度与临床疗效的关系[J].中国现代医生, 2017, 55(12): 9-12.

[18]

Terri M, Trionfetti F, Montaldo C, et al. Mechanisms of peritoneal fibrosis: focus on immune cells-peritoneal stroma interactions[J].Front Immunol, 2021, 12: 607204.

[19]

Farkas A, Oikonomou K, Ghanbar M, et al. Population pharmacokinetics of intraperitoneal gentamicin and the impact of varying dwell times on pharmacodynamic target attainment in patients with acute peritonitis undergoing peritoneal dialysis[J].Antimicrob Agents Chemother, 2022, 66(2): e01679-21.

[20]

Bonomini M, Masola V, Monaco MP, et al. Coupling osmotic efficacy with biocompatibility in peritoneal dialysis: a stiff challenge[J].Int J Mol Sci, 2024, 25(6): 3532.

[21]

Geilen J, Kainz M, Zapletal B, et al. Effects of lung inflammation and injury on pulmonary tissue penetration of meropenem and vancomycin in a model of unilateral lung injury[J].Int J Antimicrob Agents, 2024, 64(1): 107180.

[22]

Chen Z, Taubert M, Chen C, et al. Plasma and cerebrospinal fluid population pharmacokinetics of vancomycin in patients with external ventricular drain[J].Antimicrob Agents Chemother, 2023, 67(6): e00241-23.

[23]

叶寅寅, 周茹, 宋霞, 等. 万古霉素血药浓度测定在腹膜透析相关性腹膜炎患者治疗中的作用[J].重庆医科大学学报, 2021, 46(3): 350-354.

[24]

王敏, 邢玲玲, 张春霞, 等. 难治性腹膜透析相关性腹膜炎发生的影响因素及拔管风险预测[J].实用医学杂志, 2023, 39(9): 1143-1147.

基金资助

江苏省自然科学基金面上项目(BK20231199)

苏州市医疗卫生创新项目(SKY2022141)

急诊医学重庆市重点实验室开放课题(2023KFKT07)

重庆市教委科学技术研究项目(KJQN202300104)

重庆市教委科学技术研究项目(KJZD-K202300102)

AI Summary AI Mindmap
PDF (1079KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉